DG Comp issues fresh pay-for-delay charge

The EU’s competition watchdog has accused drugmaker Teva and subsidiary Cephalon – a former rival – of signing an illegal patent settlement in which Teva agreed to delay the entry of a generic sleep disorder drug.

Unlock unlimited access to all Global Competition Review content